Introduction Peripheral Vein to New Technology Group 7 with Ciltacabtagene Autoleucel, Percutaneous Approach - XW033A7
Introduction Peripheral Vein to New Technology Group 3 with Cytarabine and Daunorubicin Liposome Antineoplastic, Percutaneous Approach - XW033B3
Introduction Peripheral Vein to New Technology Group 6 with Omadacycline Anti-infective, Percutaneous Approach - XW033B6
Introduction Peripheral Vein to New Technology Group 7 with Amivantamab Monoclonal Antibody, Percutaneous Approach - XW033B7
Introduction Peripheral Vein to New Technology Group 10 with Orca-T Allogeneic T-cell Immunotherapy, Percutaneous Approach - XW033BA
Introduction Peripheral Vein to New Technology Group 6 with Eculizumab, Percutaneous Approach - XW033C6
Introduction Peripheral Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous, Percutaneous Approach - XW033C7
Introduction Peripheral Vein to New Technology Group 10 with Zanidatamab Antineoplastic, Percutaneous Approach - XW033CA
Introduction Peripheral Vein to New Technology Group 6 with Atezolizumab Antineoplastic, Percutaneous Approach - XW033D6
Introduction Peripheral Vein to New Technology Group 10 with Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension, Percutaneous Approach - XW033DA
Introduction Peripheral Vein to New Technology Group 5 with Remdesivir Anti-infective, Percutaneous Approach - XW033E5
Introduction Peripheral Vein to New Technology Group 6 with Etesevimab Monoclonal Antibody, Percutaneous Approach - XW033E6
Introduction Peripheral Vein to New Technology Group 3 with Other New Technology Therapeutic Substance, Percutaneous Approach - XW033F3
Introduction Peripheral Vein to New Technology Group 5 with Other New Technology Therapeutic Substance, Percutaneous Approach - XW033F5
Introduction Peripheral Vein to New Technology Group 6 with Bamlanivimab Monoclonal Antibody, Percutaneous Approach - XW033F6
Introduction Peripheral Vein to New Technology Group 10 with Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy, Percutaneous Approach - XW033FA
Introduction Peripheral Vein to New Technology Group 5 with Sarilumab, Percutaneous Approach - XW033G5
Introduction Peripheral Vein to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach - XW033G6
Introduction Peripheral Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic, Percutaneous Approach - XW033G7
Introduction Peripheral Vein to New Technology Group 5 with Tocilizumab, Percutaneous Approach - XW033H5
Introduction Peripheral Vein to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach - XW033H6
Introduction Peripheral Vein to New Technology Group 7 with Axicabtagene Ciloleucel Immunotherapy, Percutaneous Approach - XW033H7
Introduction Peripheral Vein to New Technology Group 7 with Tisagenlecleucel Immunotherapy, Percutaneous Approach - XW033J7
Introduction Peripheral Vein to New Technology Group 7 with Idecabtagene Vicleucel Immunotherapy, Percutaneous Approach - XW033K7
Introduction Peripheral Vein to New Technology Group 9 with Sulbactam-Durlobactam, Percutaneous Approach - XW033K9
Introduction Peripheral Vein to New Technology Group 6 with CD24Fc Immunomodulator, Percutaneous Approach - XW033L6
Introduction Peripheral Vein to New Technology Group 7 with Lifileucel Immunotherapy, Percutaneous Approach - XW033L7
Introduction Peripheral Vein to New Technology Group 7 with Brexucabtagene Autoleucel Immunotherapy, Percutaneous Approach - XW033M7
Introduction Peripheral Vein to New Technology Group 7 with Lisocabtagene Maraleucel Immunotherapy, Percutaneous Approach - XW033N7
Introduction Peripheral Vein to New Technology Group 9 with Glofitamab Antineoplastic, Percutaneous Approach - XW033P9
Introduction Peripheral Vein to New Technology Group 5 with Tagraxofusp-erzs Antineoplastic, Percutaneous Approach - XW033Q5
Introduction Peripheral Vein to New Technology Group 9 with Posoleucel, Percutaneous Approach - XW033Q9
Introduction Peripheral Vein to New Technology Group 9 with Rezafungin, Percutaneous Approach - XW033R9
Introduction Peripheral Vein to New Technology Group 5 with Iobenguane I-131 Antineoplastic, Percutaneous Approach - XW033S5
Introduction Peripheral Vein to New Technology Group 5 with Caplacizumab, Percutaneous Approach - XW033W5
Introduction Central Vein to New Technology Group 6 with Brexanolone, Percutaneous Approach - XW04306
Introduction Central Vein to New Technology Group 8 with Spesolimab Monoclonal Antibody, Percutaneous Approach - XW04308
Introduction Central Vein to New Technology Group 6 with Nerinitide, Percutaneous Approach - XW04326
Introduction Central Vein to New Technology Group 6 with Durvalumab Antineoplastic, Percutaneous Approach - XW04336
Introduction Central Vein to New Technology Group 10 with Bentracimab, Ticagrelor Reversal Agent, Percutaneous Approach - XW0433A
Introduction Central Vein to New Technology Group 10 with Cefepime-taniborbactam Anti-infective, Percutaneous Approach - XW0434A
Introduction Central Vein to New Technology Group 7 with Narsoplimab Monoclonal Antibody, Percutaneous Approach - XW04357
Introduction Central Vein to New Technology Group 8 with Mosunetuzumab Antineoplastic, Percutaneous Approach - XW04358
Introduction Central Vein to New Technology Group 10 with Ceftobiprole Medocaril Anti-infective, Percutaneous Approach - XW0435A
Introduction Central Vein to New Technology Group 6 with Lefamulin Anti-infective, Percutaneous Approach - XW04366
Introduction Central Vein to New Technology Group 7 with Terlipressin, Percutaneous Approach - XW04367
Introduction Central Vein to New Technology Group 8 with Afamitresgene Autoleucel Immunotherapy, Percutaneous Approach - XW04368
Introduction Central Vein to New Technology Group 2 with Coagulation Factor Xa, Inactivated, Percutaneous Approach - XW04372
Introduction Central Vein to New Technology Group 7 with Trilaciclib, Percutaneous Approach - XW04377
Introduction Central Vein to New Technology Group 8 with Tabelecleucel Immunotherapy, Percutaneous Approach - XW04378
Introduction Central Vein to New Technology Group 7 with Lurbinectedin, Percutaneous Approach - XW04387
Introduction Central Vein to New Technology Group 8 with Treosulfan, Percutaneous Approach - XW04388
Introduction Central Vein to New Technology Group 10 with Obecabtagene Autoleucel, Percutaneous Approach - XW0438A
Introduction Central Vein to New Technology Group 6 with Ceftolozane/Tazobactam Anti-infective, Percutaneous Approach - XW04396
Introduction Central Vein to New Technology Group 8 with Inebilizumab-cdon, Percutaneous Approach - XW04398
Introduction Central Vein to New Technology Group 10 with Odronextamab Antineoplastic, Percutaneous Approach - XW0439A
Introduction Central Vein to New Technology Group 6 with Cefiderocol Anti-infective, Percutaneous Approach - XW043A6
Introduction Central Vein to New Technology Group 7 with Ciltacabtagene Autoleucel, Percutaneous Approach - XW043A7
Introduction Central Vein to New Technology Group 3 with Cytarabine and Daunorubicin Liposome Antineoplastic, Percutaneous Approach - XW043B3
Introduction Central Vein to New Technology Group 6 with Omadacycline Anti-infective, Percutaneous Approach - XW043B6
Introduction Central Vein to New Technology Group 7 with Amivantamab Monoclonal Antibody, Percutaneous Approach - XW043B7
Introduction Central Vein to New Technology Group 10 with Orca-T Allogeneic T-cell Immunotherapy, Percutaneous Approach - XW043BA
Introduction Central Vein to New Technology Group 6 with Eculizumab, Percutaneous Approach - XW043C6
Introduction Central Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous, Percutaneous Approach - XW043C7
Introduction Central Vein to New Technology Group 10 with Zanidatamab Antineoplastic, Percutaneous Approach - XW043CA
Introduction Central Vein to New Technology Group 6 with Atezolizumab Antineoplastic, Percutaneous Approach - XW043D6
Introduction Central Vein to New Technology Group 5 with Remdesivir Anti-infective, Percutaneous Approach - XW043E5
Introduction Central Vein to New Technology Group 6 with Etesevimab Monoclonal Antibody, Percutaneous Approach - XW043E6
Introduction Central Vein to New Technology Group 3 with Other New Technology Therapeutic Substance, Percutaneous Approach - XW043F3
Introduction Central Vein to New Technology Group 5 with Other New Technology Therapeutic Substance, Percutaneous Approach - XW043F5
Introduction Central Vein to New Technology Group 6 with Bamlanivimab Monoclonal Antibody, Percutaneous Approach - XW043F6
Introduction Central Vein to New Technology Group 10 with Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy, Percutaneous Approach - XW043FA
Introduction Central Vein to New Technology Group 5 with Sarilumab, Percutaneous Approach - XW043G5
Introduction Central Vein to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach - XW043G6
Introduction Central Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic, Percutaneous Approach - XW043G7
Introduction Central Vein to New Technology Group 5 with Tocilizumab, Percutaneous Approach - XW043H5
Introduction Central Vein to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach - XW043H6
Introduction Central Vein to New Technology Group 7 with Axicabtagene Ciloleucel Immunotherapy, Percutaneous Approach - XW043H7
Introduction Central Vein to New Technology Group 7 with Tisagenlecleucel Immunotherapy, Percutaneous Approach - XW043J7
Introduction Central Vein to New Technology Group 7 with Idecabtagene Vicleucel Immunotherapy, Percutaneous Approach - XW043K7
Introduction Central Vein to New Technology Group 9 with Sulbactam-Durlobactam, Percutaneous Approach - XW043K9
Introduction Central Vein to New Technology Group 6 with CD24Fc Immunomodulator, Percutaneous Approach - XW043L6
Introduction Central Vein to New Technology Group 7 with Lifileucel Immunotherapy, Percutaneous Approach - XW043L7
Introduction Central Vein to New Technology Group 7 with Brexucabtagene Autoleucel Immunotherapy, Percutaneous Approach - XW043M7
Introduction Central Vein to New Technology Group 7 with Lisocabtagene Maraleucel Immunotherapy, Percutaneous Approach - XW043N7
Introduction Central Vein to New Technology Group 9 with Glofitamab Antineoplastic, Percutaneous Approach - XW043P9
Introduction Central Vein to New Technology Group 5 with Tagraxofusp-erzs Antineoplastic, Percutaneous Approach - XW043Q5
Introduction Central Vein to New Technology Group 9 with Posoleucel, Percutaneous Approach - XW043Q9
Introduction Central Vein to New Technology Group 9 with Rezafungin, Percutaneous Approach - XW043R9
Introduction Central Vein to New Technology Group 5 with Iobenguane I-131 Antineoplastic, Percutaneous Approach - XW043S5
Introduction Central Vein to New Technology Group 5 with Caplacizumab, Percutaneous Approach - XW043W5
Introduction Peripheral Artery to New Technology Group 9 with Melphalan Hydrochloride Antineoplastic, Percutaneous Approach - XW053T9
Introduction Mouth and Pharynx to New Technology Group 8 with Maribavir Anti-infective, External Approach - XW0DX38
Introduction Mouth and Pharynx to New Technology Group 6 with Lefamulin Anti-infective, External Approach - XW0DX66
Introduction Mouth and Pharynx to New Technology Group 2 with Uridine Triacetate, External Approach - XW0DX82
Introduction Mouth and Pharynx to New Technology Group 5 with Other New Technology Therapeutic Substance, External Approach - XW0DXF5
Introduction Mouth and Pharynx to New Technology Group 9 with Quizartinib Antineoplastic, External Approach - XW0DXJ9
Introduction Mouth and Pharynx to New Technology Group 8 with Sabizabulin, External Approach - XW0DXK8
Introduction Mouth and Pharynx to New Technology Group 6 with Baricitinib, External Approach - XW0DXM6
Introduction Mouth and Pharynx to New Technology Group 9 with SER-109, External Approach - XW0DXN9
